QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
NASDAQ:AVIR

Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

$4.09
+0.09 (+2.25%)
(As of 12:03 PM ET)
Today's Range
$3.98
$4.09
50-Day Range
$3.57
$4.56
52-Week Range
$2.77
$5.19
Volume
65,222 shs
Average Volume
483,746 shs
Market Capitalization
$344.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Atea Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Atea Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$327,852 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.76) to ($2.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.77 out of 5 stars

Medical Sector

818th out of 939 stocks

Pharmaceutical Preparations Industry

380th out of 435 stocks

AVIR stock logo

About Atea Pharmaceuticals Stock (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

AVIR Stock Price History

AVIR Stock News Headlines

Atea Pharmaceuticals, Inc.
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
AVIR Apr 2024 2.500 call
AVIR Mar 2024 7.500 call
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Recap: Atea Pharmaceuticals Q4 Earnings
Atea Pharmaceuticals Inc Ordinary Shares
Atea Pharmaceuticals Inc Ordinary Shares
Q3 2023 Atea Pharmaceuticals Inc Earnings Call
Atea Pharmaceuticals GAAP EPS of -$0.40
See More Headlines
Receive AVIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AVIR
Fax
N/A
Employees
75
Year Founded
N/A

Profitability

Net Income
$-135,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$351.37 million
Book Value
$6.65 per share

Miscellaneous

Free Float
71,961,000
Market Cap
$336.66 million
Optionable
Optionable
Beta
0.17
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Jean-Pierre Sommadossi Ph.D. (Age 68)
    Founder, Chairman, CEO & President
    Comp: $1.1M
  • Ms. Andrea J. Corcoran J.D. (Age 62)
    CFO, Executive VP of Legal & Secretary
    Comp: $732.45k
  • Mr. John F. Vavricka (Age 60)
    Chief Commercial Officer
    Comp: $581.11k
  • Dr. Janet M. J. Hammond M.D. (Age 63)
    Ph.D., Chief Development Officer
    Comp: $817.16k
  • Dr. Maria Arantxa Horga M.D. (Age 55)
    Chief Medical Officer
    Comp: $695.85k
  • Mr. Wayne Foster CPA (Age 55)
    Executive VP of Finance & Chief Accounting Officer
  • Ms. Jonae R. Barnes
    Senior Vice President of Investor Relations & Corporate Communications
  • Mr. Ariyapadi N. Krishnaraj
    Vice President of Marketing
  • Mr. Adel Moussa Ph.D.
    Executive Vice President of Chemistry
  • Mr. Xiao-Jian Zhou Ph.D.
    Executive Vice President of Early Stage Development

AVIR Stock Analysis - Frequently Asked Questions

Should I buy or sell Atea Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" AVIR shares.
View AVIR analyst ratings
or view top-rated stocks.

How have AVIR shares performed in 2024?

Atea Pharmaceuticals' stock was trading at $3.05 at the start of the year. Since then, AVIR stock has increased by 31.1% and is now trading at $4.00.
View the best growth stocks for 2024 here
.

When is Atea Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our AVIR earnings forecast
.

How were Atea Pharmaceuticals' earnings last quarter?

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) posted its earnings results on Wednesday, February, 28th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.03.

What ETFs hold Atea Pharmaceuticals' stock?

ETFs with the largest weight of Atea Pharmaceuticals (NASDAQ:AVIR) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and Amplify Treatments, Testing and Advancements ETF (GERM).iShares U.S. Pharmaceuticals ETF (IHE).

When did Atea Pharmaceuticals IPO?

Atea Pharmaceuticals (AVIR) raised $253 million in an IPO on Friday, October 30th 2020. The company issued 11,000,000 shares at a price of $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair served as the underwriters for the IPO.

Who are Atea Pharmaceuticals' major shareholders?

Atea Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (6.55%), Vanguard Group Inc. (5.51%), Vanguard Group Inc. (5.46%), Stonepine Capital Management LLC (1.01%), Northern Trust Corp (0.85%) and Federated Hermes Inc. (0.71%). Insiders that own company stock include Andrea Corcoran, Franklin M Berger, Jean-Pierre Sommadossi, Polly A Murphy and Wayne Foster.
View institutional ownership trends
.

How do I buy shares of Atea Pharmaceuticals?

Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVIR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners